Below are the top 10 U.S.-listed Chinese stocks with highest upside potential,
UPDATED TODAY before 4:30 AM ET, based on the difference between current price
and Wall Street analysts average target price. China Education Alliance, Inc.
(NYSE:CEU) has the 1st highest upside potential in this segment of the market.
Its upside is 240.0%. Its consensus target price is $8.50 based on the average
of all estimates. NIVS IntelliMedia Technology Group Inc (NYSE:NIV) has the 2nd
highest upside potential in this segment of the market. Its upside is 222.6%.
Its consensus target price is $7.00 based on the average of all estimates.
SkyPeople Fruit Juice, Inc. (NASDAQ:SPU) has the 3rd highest upside potential in
this segment of the market. Its upside is 200.2%. Its consensus target price is
$13.00 based on the average of all estimates. NF Energy Saving Corp
(NASDAQ:NFEC) has the 4th highest upside potential in this segment of the
market. Its upside is 172.9%. Its consensus target price is $12.50 based on the
average of all estimates. Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) has the
5th highest upside potential in this segment of the market. Its upside is
156.4%. Its consensus target price is $7.00 based on the average of all
estimates. China Ritar Power Corp. (NASDAQ:CRTP) has the 6th highest upside
potential in this segment of the market. Its upside is 150.6%. Its consensus
target price is $6.67 based on the average of all estimates. Xinyuan Real Estate
Co., Ltd. (ADR) (NYSE:XIN) has the 7th highest upside potential in this segment
of the market. Its upside is 143.3%. Its consensus target price is $6.67 based
on the average of all estimates. ZST Digital Networks Inc (NASDAQ:ZSTN) has the
8th highest upside potential in this segment of the market. Its upside is
141.7%. Its consensus target price is $16.00 based on the average of all
estimates. Shiner International, Inc. (NASDAQ:BEST) has the 9th highest upside
potential in this segment of the market. Its upside is 125.6%. Its consensus
target price is $3.00 based on the average of all estimates. China Nuokang
Bio-Pharmaceutical Inc. (NASDAQ:NKBP) has the 10th highest upside potential in
this segment of the market. Its upside is 125.4%. Its consensus target price is
$8.25 based on the average of all estimates.
No comments:
Post a Comment